RNA, U6 small nuclear 834, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-834P profile across patient tissues and cancer cell-line models. RNU6-834P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-834P is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, RNU6-834P RNA expression shows 15,303 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, and DLBC as cancer lineages where RNU6-834P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-834P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-834P survival associations across molecular data types. RNU6-834P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-834P RNA expression–survival associations across cancer types. High RNU6-834P expression shows unfavorable associations in COAD, KIRC, CHOL, STAD and LUSC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for RNU6-834P RNA expression.
This table summarizes RNU6-834P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-834P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-834P shows lower tumor expression in THCA and higher tumor expression in BLCA, LUSC, KICH, STAD and CHOL. The BLCA box plot shows higher RNU6-834P RNA expression in tumor versus normal tissue (log2 FC = +0.626, t-test p = .037).
This table shows molecular features associated with RNU6-834P in patient tissues and cancer cell lines. In patient samples, RNU6-834P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
